# Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors

DAVID S. GOLDFARB, PATRICIA A. MacDONALD, BARBARA HUNT, and LHANOO GUNAWARDHANA

*ABSTRACT.* ***Objective.*** Hyperuricemia of gout can arise due to either overproduction or underexcretion of uric acid. Not all available urate-lowering therapies are equally effective and safe for use in patients with renal disease. The objective of this post-hoc analysis was to determine the effectiveness of the xanthine oxidase inhibitor febuxostat in reducing serum urate (sUA) levels in gouty patients who were either overproducers or underexcretors.

***Methods.*** Gouty subjects 18 to 85 years of age with sUA ≥ 8.0 mg/dl at baseline were enrolled in a Phase 2, 28-day, multicenter, randomized, double-blind, placebo-controlled trial and randomized to receive febuxostat 40 mg, 80 mg, or 120 mg daily, or placebo. The primary efficacy endpoint was the proportion of subjects with sUA < 6.0 mg/dl at Day 28. Secondary efficacy endpoints included percentage reductions in sUA and urinary uric acid (uUA) from baseline to Day 28.

***Results.*** Of the 153 subjects, 118 (77%) were underexcretors (uUA ≤ 800 mg/24 h) and 32 (21%) were overproducers (uUA > 800 mg/24 h); baseline uUA data were missing for 3 subjects. Treatment with febuxostat led to the majority of subjects achieving sUA < 6.0 mg/dl at Day 28. Treatment with any dose of febuxostat led to significantly greater percentage reductions in uUA than that observed in the placebo group, for both underexcretors and overproducers.

***Conclusion.*** Febuxostat is a highly efficacious urate-lowering therapy in patients with gout regardless of overproduction or underexcretion status. (First Release May 15 2011; J Rheumatol 2011;38:1385–9; doi:10.3899/jrheum.101156)

*Key Indexing Terms:*
FEBUXOSTAT ALLOPURINOL GOUT
HYPERURICEMIA URIC ACID EXCRETION

Gout is characterized by hyperuricemia [serum urate (sUA) concentration > 6.8 mg/dl, the limit of urate solubility] and by the acute and chronic consequences of monosodium urate crystal deposition, including gout flares, tophi, arthropathy, and increased likelihood for nephrolithiasis[1,2,3]. Hyperuricemia can arise due to either overproduction (10% of patients) or underexcretion (90% of patients) of urate, or a combination of both[4].

Urate-lowering therapy (ULT) is used for achieving and maintaining subsaturated goal sUA < 6.0 mg/dl, with the aim of dissolving and eliminating urate crystal deposits and the possibility of crystal-associated inflammation[5,6,7,8]. ULT options available in the United States include the xanthine oxidase (XO) inhibitors allopurinol and febuxostat, and the uricosuric probenecid. Probenecid is not effective in gout patients with renal impairment[9] and should not be used in patients with nephrolithiasis or in those who overproduce uric acid (vs underexcretors), as therapy can lead to deposition of uric acid crystals in the renal tubules, further development of stones, and worsening of renal function[10,11]. Allopurinol, the only XO inhibitor available until recently, is efficacious in both urate overproducers and underexcretors[12].

Febuxostat is a selective nonpurine analog XO inhibitor[13] approved in the United States and European Union for the treatment of chronic hyperuricemia in patients with gout[14,15]. Data from 3 comparative randomized controlled trials[16,17,18] have demonstrated the superior efficacy of febuxostat 80 mg daily compared to both allopurinol 300 mg[19,20] and placebo. In addition, febuxostat 40 mg daily was shown to be non-inferior to allopurinol[18]. The objective of this subanalysis was to determine if febuxostat was equally efficacious in gout patients with hyperuricemia, whether caused by overproduction or underexcretion of uric acid. Given the comparable efficacy of allopurinol in these 2 populations of people with hyperuricemia, we expected that febuxostat would also be effective in both groups.

*From the New York Veterans Affairs Medical Center and New York University Langone Medical Center (NYULMC), New York, New York; and Takeda Global Research and Development Center, Inc., Deerfield, Illinois, USA.*

*Supported by Takeda Global Research and Development Center, Inc. The original phase 2 study was funded by TAP Pharmaceutical Products, Inc. (now a part of Takeda Global Research and Development Center, Inc.), and was registered with clinicaltrials.gov, NCT00174967. Dr. Goldfarb has served as a consultant for Takeda Pharmaceuticals North America, Inc., and has received research funding from Kibow, Amgen, the NIDDK, and the ORDR via grant 1U54DK083908-01.*

*D.S. Goldfarb, MD, Clinical Chief, Nephrology, NYULMC, Professor of Medicine and Physiology, NYU School of Medicine; P.A. MacDonald, RN, NP, Associate Director, Rheumatology/GI Therapeutic Area; B. Hunt, MS, Director, Statistics; L. Gunawardhana, MD, PhD, Associate Medical Director, Pain and Inflammation, Clinical Science, Takeda Global Research and Development Center, Inc.*

*Address correspondence to Dr. D.S. Goldfarb, NYU School of Medicine, Nephrology/111G, 423 East 23rd Street, New York, NY 10010. E-mail: david.goldfarb@nyumc.org*

*Accepted for publication February 8, 2011.*

## MATERIALS AND METHODS

As described[21], subjects who met the American Rheumatology Association[22] criteria for primary gout were enrolled in a 28-day, multicenter, Phase 2, randomized, blinded, placebo-controlled trial if they met all inclusion and none of the exclusion criteria. Patients, male or female, had to be 18 to 85 years of age with sUA ≥ 8.0 mg/dl at baseline. Exclusion criteria included serum creatinine (sCr) > 1.5 mg/dl or estimated creatinine clearance (eClcr; calculated by Cockcroft-Gault method[23]) < 50 ml/min; concurrent use of other ULT or medications containing aspirin (> 325 mg) or other salicylates; a history of xanthinuria, active liver disease, or hepatic dysfunction; or a history of alcohol abuse or intake of ≥ 14 alcoholic drinks per week.

After a 2-week washout for those subjects already receiving ULT, subjects were randomized 1:1:1:1 to receive febuxostat 40, 80, or 120 mg daily or placebo. For all subjects, colchicine 0.6 mg twice daily was provided for flare prophylaxis during the washout period and the first 2 weeks of the double-blind treatment. During weekly visits, including at enrollment (baseline visit), sUA was measured using an enzymatic method, and adverse events (AE) were recorded. At baseline and final visit at Day 28, 24-hour urine collection was carried out for measurement of urinary uric acid (uUA) and Clcr—uUA was measured by a standard uricase-dependent color assay on a Hitachi 911 analyzer. Subjects were classified as either underexcretors (uUA ≤ 800 mg/24 h) or overproducers (uUA > 800 mg/24 h) at baseline.

The primary efficacy endpoint was the proportion of subjects with sUA < 6.0 mg/dl at Day 28. Secondary efficacy endpoints included percentage reductions in sUA and uUA from baseline to Day 28. Baseline demographics, gout and comorbid characteristics, and efficacy endpoints are stratified here by baseline uUA status (underexcretor vs overproducer). AE rates are reported by treatment group.

## RESULTS

Of the 153 subjects enrolled, 118 (77%) were underexcretors and 32 (21%) were overproducers. This analysis of the primary efficacy endpoint excluded 15 subjects due to missing baseline sUA or uUA. Baseline demographics and gout and comorbid disease characteristics, except for the percentage of subjects with tophi, were similar across treatment groups, regardless of baseline uUA (Table 1). Baseline sUA did not differ in the 2 groups.

Treatment with any dose of febuxostat led to the majority of subjects achieving sUA < 6.0 mg/dl at Day 28 in both overproducers and underexcretors (Figure 1). There was a trend for febuxostat 40 mg to be more efficacious in overproducers, but the number of subjects in each baseline uUA category in each treatment group was too low to determine significance.

The percentage change in sUA from baseline to Day 28 was similar between overproducers and underexcretors among all treatment groups; however, the mean percentage change was numerically greater for underexcretors in each treatment group and the difference between overproducers and underexcretors was greatest in the febuxostat 40 mg group (Figure 2).

Mean percentage change in uUA and Clcr from baseline to Day 28 is provided in Table 2. Treatment with any dose of febuxostat led to significantly greater percentage reductions in uUA than that observed in the placebo group, for both underexcretors and overproducers ($p \leq 0.002$). There was no significant influence on Clcr ($p = 0.422$), regardless of treatment group or baseline uUA status.

The most frequently reported AE were diarrhea and pain, reported by 17 (11%) and 15 (10%) of all subjects (N = 153), respectively. Rates of AE were generally similar across treatment groups (Table 3).

## DISCUSSION

This is the first study to assess the efficacy of febuxostat specifically in uric acid overproducers and underexcretors. In the United States, febuxostat is approved for use as ULT in gout patients at 40 mg and 80 mg daily doses[14]. Initial examination of Figure 1 suggests comparable efficacy of febuxostat in both overproducers and underexcretors at the 80 mg dose, and perhaps more so in overproducers at 40 mg, based on the proportion of subjects achieving final sUA < 6.0 mg/dl. Efficacy in overproducers and underexcretors appears similar at the 120 mg dose; this dose is not approved for use in the United States[14]. However, when efficacy is assessed by change in sUA from baseline, underexcretors appear to experience a numerically greater benefit at 40 or 80 mg than do overproducers (Figure 2). The numbers of subjects in each uUA category are small, limiting the interpretation of these data. Together, the data presented in the 2 figures suggest that febuxostat is comparably efficacious in both overproducers and underexcretors at 40 mg and 80 mg.

Increases in sUA due to overproduction can arise because of an underlying condition, inherited metabolic error, or excessive consumption of purine-rich animal protein, fructose, or alcohol[4]. The majority of patients with endogenous overproduction of urate are hyperuricemic because of salvaged purines that arise from increased cell turnover in proliferative and inflammatory disorders (e.g., hematologic cancer or psoriasis), from pharmacologic intervention resulting in increased urate production (e.g., chemotherapy), or from tissue hypoxia[4]. Only a small portion of urate overproducers (~ 10%) have well characterized inborn errors of metabolism, such as 5′-phosphoribosyl-1-pyrophosphate synthetase superactivity or hypoxanthine-guanine phosphoribosyl transferase deficiency[4]. For such patients with overproduction of uric acid, inhibition of XO-mediated uric acid production is an attractive therapeutic option.

However, most patients with gout and hyperuricemia are not overproducers but underexcretors. Perez-Ruiz, *et al*[24] examined the change in renal handling among 25 gout subjects considered overproducers (uUA > 700 mg/day) by comparing various measures of urate renal handling before and after ULT with allopurinol. Their results suggest that even among overproducers, renal urate excretion is lower than in normouricemic adults[24].

Roughly two-thirds of urate excretion occurs by the kidney, while the remainder is excreted by the gastrointestinal tract[25]. In normouricemic adults, the fractional excretion of urate by the kidney is < 10%[26]. Recent identification and characterization of urate transport proteins in the proximal tubule provide evidence for the complicated processes of urate reabsorption and excretion that ultimately determine the amount

*Table 1.* Baseline characteristics and demographics by treatment group and urinary uric acid status.

| Variable | Underexcretors | | | | Overproducers | | | |
|---|---|---|---|---|---|---|---|---|
| | Febuxostat | | | | Febuxostat | | | |
| | 40 mg, N = 29 | 80 mg, N = 29 | 120 mg, N = 30 | Placebo, N = 30 | 40 mg, N = 8 | 80 mg, N = 9 | 120 mg, N = 7 | Placebo, N = 8 |
| Male, n (%) | 25 (86) | 27 (93) | 25 (83) | 24 (80) | 8 (100) | 9 (100) | 7 (100) | 8 (100) |
| Age, yrs, mean ± SD | 54 ± 13.3 | 57 ± 11.7 | 56 ± 11.0 | 53 ± 11.5 | 46 ± 15.9 | 45 ± 11.4 | 56 ± 11.8 | 50 ± 17.0 |
| Body mass index (kg/m$^2$), n | 29 | 29 | 29 | 30 | 8 | 9 | 7 | 8 |
| Mean ± SD | 32 ± 4.7 | 33 ± 6.5 | 30 ± 5.0 | 32 ± 5.0 | 30 ± 3.7 | 35 ± 7.3 | 36 ± 8.0 | 31 ± 4.4 |
| Tophi present, n (%) | 5 (17) | 7 (24) | 10 (33) | 9 (30) | 1 (13) | 1 (11) | 0 | 0 |
| Nephrolithiasis present, n (%) | 2 (7) | 4 (14) | 1 (3) | 3 (10) | 0 | 3 (33) | 0 | 0 |
| Serum urate (mg/dl), n | 27 | 27 | 28 | 28 | 7 | 8 | 6 | 7 |
| Mean ± SD | 9.3 ± 0.95 | 10.0 ± 1.31 | 9.5 ± 1.09 | 9.9 ± 1.42 | 8.9 ± 0.88 | 9.8 ± 1.49 | 10.1 ± 1.13 | 9.7 ± 0.94 |
| Urine uric acid (mg/day), n | 26 | 27 | 28 | 27 | 7 | 8 | 6 | 7 |
| Mean ± SD | 494 ± 162.5 | 523 ± 155.1 | 473 ± 180.3 | 507 ± 139.0 | 982 ± 178.0 | 1065 ± 336.9 | 1006 ± 206.5 | 934 ± 135.5 |
| Creatinine clearance (ml/min), n | 29 | 28 | 29 | 29 | 8 | 9 | 6 | 8 |
| Mean ± SD | 70 ± 15.4 | 72 ± 18.6 | 64 ± 18.1 | 69 ± 21.5 | 99 ± 31.3 | 112 ± 37.7 | 108 ± 39.4 | 97 ± 8.8 |
| Comorbidities, n (%) | | | | | | | | |
| Cardiovascular disease | 6 (21) | 6 (21) | 6 (20) | 9 (30) | 1 (13) | 0 | 3 (43) | 2 (25) |
| Congestive heart failure | 0 | 4 (14) | 0 | 0 | 0 | 0 | 0 | 1 (13) |
| Diabetes | 5 (17) | 7 (24) | 3 (10) | 2 (7) | 1 (13) | 1 (11) | 1 (14) | 0 |
| Hypercholesterolemia | 4 (14) | 6 (21) | 5 (17) | 2 (7) | 2 (25) | 1 (11) | 2 (29) | 1 (13) |
| Hyperlipidemia | 12 (41) | 15 (52) | 13 (43) | 13 (43) | 4 (50) | 3 (33) | 5 (71) | 4 (50) |
| Hypertension | 13 (45) | 16 (55) | 16 (53) | 17 (57) | 2 (25) | 2 (22) | 3 (43) | 3 (38) |
| Obesity | 4 (14) | 12 (41) | 6 (20) | 8 (27) | 1 (13) | 4 (44) | 4 (57) | 2 (25) |




*Figure 1.* Treatment with any dose of febuxostat led to the majority of subjects achieving sUA < 6.0 mg/dl at Day 28 in both overproducers and underexcretors.

of urate excreted by the kidneys[27]. Deficient renal urate excretion could occur because of decreased glomerular filtration, increased urate reabsorption in the proximal tubule, or decreased tubular urate secretion. Although all these mechanisms may contribute to decreased renal clearance of urate, decreased tubular secretion may be the most prominent and widely prevalent disorder accounting for most cases of gout and hyperuricemia. Despite the frequency of this abnormality in renal handling of urate, inhibition of XO activity is considered the treatment of choice regardless of a patient's underlying mechanism of hyperuricemia[8]. As the goal of gout therapy is to lower sUA and thereby promote crystal dissolution and prevent crystal formation, success is not determined by whether pathophysiologic mechanisms specific to a patient are attacked. Current guidelines regarding gout management therefore do not recommend distinguishing underexcretors




*Figure 2*. The percentage change in sUA from baseline to Day 28 was similar between overproducers and underexcretors among all treatment groups; the mean percentage change was numerically greater for underexcretors in each treatment group and the difference between overproducers and underexcretors was greatest in the febuxostat 40 mg group.

*Table 2*. Mean percentage reduction in urinary uric acid and creatinine clearance from baseline.

| | Febuxostat 40 mg | | Febuxostat 80 mg | | Febuxostat 120 mg | | Placebo | |
|---|---|---|---|---|---|---|---|---|
| | N | Mean ± SD | N | Mean ± SD | N | Mean ± SD | N | Mean ± SD |
| Urinary uric acid, mg/day | | | | | | | | |
| Underexcretors | 26 | –39 ± 30.5 | 27 | –43 ± 28.9 | 28 | –42 ± 29.4 | 27 | 12 ± 36.6 |
| Overproducers | 7 | –61 ± 11.5 | 8 | –60 ± 12.5 | 6 | –62 ± 30.8 | 7 | –16 ± 32.6 |
| Creatinine clearance, ml/min | | | | | | | | |
| Underexcretors | 28 | 2 ± 18.9 | 25 | 1 ± 13.4 | 23 | 9 ± 19.0 | 25 | 6 ± 16.7 |
| Overproducers | 8 | –11 ± 18.3 | 9 | –18 ± 52.1 | 5 | –9 ± 19.6 | 7 | –10 ± 29.7 |

from overproducers. Whether there is any difference in the relative efficacy of febuxostat and allopurinol in overproducers or underexcretors is not established by our study.

Comparisons of the uricosuric agents probenecid and sulfinpyrazone are scanty and inadequate, but the European League Against Rheumatism guidelines rate them as "probably inferior to allopurinol in lowering sUA"[8]. Both are less effective in the presence of chronic kidney disease and unlike XO inhibitors, relatively contraindicated in a patient with low urine pH or a history of nephrolithiasis.

Although allopurinol demonstrates equal efficacy in both types of hyperuricemia in gout patients[12], it is recommended that allopurinol dosing be adjusted in gout patients with renal impairment[8,28]. Although the direction of the causal relationships is a topic of current investigation, a reduction in glomerular filtration rate is often one contributor to underexcretion of uric acid. At both approved doses (40 mg and 80 mg), febuxostat is equally or more efficacious than allopurinol among gout subjects with mild (Stage 2, eClcr 60–89 ml/min) or moderate (Stage 3, eCLcr 30–59 ml/min) renal impairment[18]. Dose adjustment of febuxostat for patients with mild or moderate renal impairment is not needed[14]. The efficacy and safety of febuxostat in gout subjects with severe (eCLcr < 30 ml/min) renal impairment has not yet been evaluated.

These initial results demonstrate that treatment with febuxostat does not require measurement of baseline uUA excretion, as the proportions of subjects who are either overproducers or underexcretors achieving sUA < 6.0 mg/dl after 4 weeks of treatment are comparable to those reported in the longer Phase 3 trials[16,17,18]. Additional analyses of febuxostat efficacy in larger numbers of overproducers and underexcretors are needed to verify the results reported here. In those responsive to ULT, longterm use has been shown to improve the clinical outcomes of gout by reducing acute flares and reducing tophi[29,30]. Thus, treatment with febuxostat provides an effective, well tolerated therapeutic option for the longterm management of gout, regardless of a patient's uUA.

## ACKNOWLEDGMENT

Assistance in manuscript preparation was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, Radnor, PA.

*Table 3*. Most frequent adverse events (reported by ≥ 2 subjects in any treatment group).

| | Febuxostat | | | |
|---|---|---|---|---|
| | 40 mg, N = 37 | 80 mg, N = 40 | 120 mg, N = 38 | Placebo, N = 38 |
| Total subjects with ≥ 1 adverse event, n (%) | 20 (54) | 23 (58) | 19 (50) | 19 (50) |
| Adverse event*, n (%) | | | | |
| Diarrhea | 1 (3) | 8 (20) | 4 (11) | 4 (11) |
| Pain | 6 (16) | 3 (8) | 2 (5) | 4 (11) |
| Back pain | 3 (8) | 2 (5) | 3 (8) | 1 (3) |
| Headache | 3 (8) | 2 (5) | 2 (5) | 1 (3) |
| Abdominal pain | 1 (3) | 1 (3) | 2 (5) | 3 (8) |
| Myalgia | 1 (3) | 1 (3) | 2 (5) | 2 (5) |
| Liver function tests abnormal | 2 (5) | 1 (3) | 1 (3) | 1 (3) |
| Arthralgia | 2 (5) | 1 (3) | 2 (5) | 0 (0) |
| Flu syndrome | 1 (3) | 0 (0) | 1 (3) | 2 (5) |
| Rash | 0 (0) | 1 (3) | 3 (8) | 0 (0) |
| Infection | 1 (3) | 0 (00 | 1 (3) | 2 (5) |
| Pharyngitis | 0 (0) | 1 (3) | 0 (0) | 2 (5) |
| Dyspepsia | 1 (3) | 2 (5) | 0 (0) | 0 (0) |
| Accidental injury | 0 (0) | 2 (5) | 1 (3) | 0 (0) |
| Increased appetite | 2 (5) | 0 (0) | 0 (0) | 0 (0) |

* Adverse events reported with Coding Symbols for a Thesaurus of Adverse Reaction Terms.

## REFERENCES


1. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008;20:167-72.
2. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
3. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int 2003;64:1022-6.
4. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
5. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
6. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
7. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-8.
8. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
9. Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum 1959;2:193-202.
10. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64:2399-416.
11. Kenny JE, Goldfarb DS. Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep 2010;12:125-9.
12. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998;57:545-9.
13. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005;76:1835-47.
14. Uloric® full prescribing information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc.; 2009.
15. European Medicines Agency. European Public Assessment Report for Adenuric. London: European Medicines Agency; 2010.
16. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
17. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
18. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
19. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
20. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008;67:609-13.
21. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
22. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002;47:610-3.
25. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006;65:981-2.
26. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998;32:917-33.
27. Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology 2009;48:222-6.
28. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
29. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-8.
30. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009;48:188-94.